Sensorimotor outcomes in adrenomyeloneuropathy show significant disease progression

被引:2
|
作者
Keller, Jennifer L. [1 ]
Eloyan, Ani [2 ]
Raymond, Gerald, V [1 ,3 ,4 ]
Fatemi, Ali [1 ,4 ]
Zackowski, Kathleen M. [1 ,4 ,5 ]
机构
[1] Kennedy Krieger Inst, Baltimore, MD 21205 USA
[2] Brown Univ, Sch Publ Hlth, Dept Biostat, Providence, RI USA
[3] Johns Hopkins Sch Med, Dept Genet Med, Baltimore, MD USA
[4] Johns Hopkins Sch Med, Dept Neurol, Baltimore, MD USA
[5] Johns Hopkins Sch Med, Dept Phys Med & Rehabil, Baltimore, MD USA
关键词
balance; biomarkers; disease progression; leukodystrophy; myelopathy; peroxisomal disorder; SPINAL-CORD-INJURY; POSTURAL SWAY; ADRENOLEUKODYSTROPHY; PERFORMANCE; STRENGTH;
D O I
10.1002/jimd.12457
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Current outcomes used to evaluate adrenomyeloneuropathy are limited by rater bias, not sensitive to preclinical changes, and require years to decades to detect disease progression. Quantitative outcomes are needed that detect meaningful change in a short time period over a broad range of disability. The study aim was to track sensorimotor outcomes in adults with adrenomyeloneuropathy and evaluate differences in progression between men and women. This prospective observational cohort study analyzes data collected annually in the Phase III study of adults with adrenomyeloneuropathy. Outcomes include postural sway in four static standing conditions, great-toe vibration, hip strength, walking velocity, timed up-and-go, and 6-minute walk distance. Linear mixed model analysis was used to detect change in the outcomes in 2 years, correcting for age, sex, disability, symptom duration, and treatment across the cohort. Modeling was repeated for each sex to evaluate differences. Power computations were carried out by sex and for the full dataset. Sixty-one men and 87 women participated. Average age, 46 +/- 12 years; Expanded Disability Status Scale, 3 (1-6.5); symptom duration, 10.8 +/- 9.4 years. The cohort showed significant worsening in all standing conditions (P < .001), sensation (P = .0223) and strength (P = .001); but more stability in walking with only velocity (P < .0337) significantly declining. For each sex, postural sway declines significantly in all conditions (P < .01) except for eyes closed feet together for women. Strength declines significantly by sex for hip flexion (P < .03). Sex-specific significant decline is seen in walking (velocity P = .0276; distance P = .0072) for men only. Quantitative measures of postural sway, sensation strength, and walking are effective measures of adrenomyeloneuropathy progression in 2 years.
引用
收藏
页码:308 / 317
页数:10
相关论文
共 50 条
  • [21] Disease Progression in Huntington Disease: An Analysis of Multiple Longitudinal Outcomes
    Garcia, Tanya P.
    Wang, Yuanjia
    Shoulson, Ira
    Paulsen, Jane S.
    Marder, Karen
    [J]. JOURNAL OF HUNTINGTONS DISEASE, 2018, 7 (04) : 337 - 344
  • [22] Disease progression and outcomes in chronic kidney disease and renal transplantation
    Djamali, A
    Kendziorski, C
    Brazy, PC
    Becker, BN
    [J]. JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY, 2003, 14 : 191A - 191A
  • [23] Disease progression and outcomes in chronic kidney disease and renal transplantation
    Djamali, A
    Kendziorski, C
    Brazy, PC
    Becker, BN
    [J]. KIDNEY INTERNATIONAL, 2003, 64 (05) : 1800 - 1807
  • [24] Disease progression is significant in terms of functional impairment but not disease activity in patients with ankylosing spondylitis
    Stone, Millicent A.
    Gordon, Derek
    Sengupta, Raj
    Pomeroy, Emma
    Mogg, Rebecca
    Keat, Andrew
    [J]. RHEUMATOLOGY, 2008, 47 : II71 - II71
  • [25] Musicians with embouchure dystonia show primary sensorimotor overactivity
    Haslinger, B.
    Altenmueller, E.
    Castrop, F.
    Zimmer, C.
    Dresel, C.
    [J]. MOVEMENT DISORDERS, 2009, 24 : S89 - S89
  • [27] Quality measures in Parkinson disease What do the outcomes show?
    Tarolli, Christopher G.
    Barbano, Richard
    [J]. NEUROLOGY-CLINICAL PRACTICE, 2020, 10 (01) : 5 - 6
  • [28] ADRENOMYELONEUROPATHY, A COMMON-CAUSE OF ADDISONS-DISEASE
    SCHAFER, JR
    EHLENZ, K
    STEINMETZ, A
    PILZ, C
    HUNNEMAN, DH
    BAERWALD, C
    VONWICHERT, P
    KAFFARNIK, H
    [J]. DEUTSCHE MEDIZINISCHE WOCHENSCHRIFT, 1994, 119 (10) : 327 - 331
  • [29] Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects
    Benito-León, J
    [J]. NEUROLOGY, 2005, 64 (10) : 1824 - 1824
  • [30] Compassionate use of quinacrine in Creutzfeldt-Jakob disease fails to show significant effects
    Haïk, S
    Brandel, JP
    Salomon, D
    Sazdovitch, V
    Delasnerie-Laupretre, N
    Laplanche, JL
    Faucheux, BA
    Soubrié, C
    Boher, E
    Belorgey, C
    Hauw, JJ
    Alpérovitch, A
    [J]. NEUROLOGY, 2004, 63 (12) : 2413 - 2415